Innoviva, Inc. (INVA) SEC Filings

Innoviva, Inc. (INVA) reported an insider transaction by Chief Financial Officer Stephen Basso. On August 20, 2026, 558 shares of common stock were disposed of at $21.00 per share to satisfy income tax withholding obligations related to the quarterly vesting of previously granted employee equity awards. Following this withholding, Basso beneficially owns 88,013 shares of Innoviva common stock held directly.

Innoviva, Inc. (INVA) reported an insider tax-related share withholding by Chief Executive Officer and director Pavel Raifeld. On 2026-08-20, 1,130 shares of common stock were disposed of at $21.00 per share to satisfy income tax withholding obligations tied to the quarterly vesting of previously granted equity awards. Following this withholding transaction, Raifeld directly owned 284,799 shares of Innoviva common stock.

Innoviva, Inc. reported Q2 2026 total revenue of $119.6 million, up from $100.3 million a year earlier, with income from operations of $50.9 million. The quarter nevertheless showed a net loss of $83.4 million, mainly from a $131.8 million unrealized loss on Armata equity holdings and $29.2 million losses on other investments.

For the first six months of 2026, total revenue reached $217.6 million and net income was $103.2 million, compared with $188.9 million in revenue and $17.1 million in net income in 2025, helped by earlier-period fair‑value gains and higher net product sales, particularly GIAPREZA and XACDURO.

Cash and cash equivalents were $570.4 million as of June 30, 2026, against $258.5 million of long‑term convertible notes, and stockholders’ equity was $1.23 billion. The company repurchased 2.37 million shares in the first half of 2026 for approximately $51.8 million.

Innoviva, Inc. reported second quarter 2026 results featuring higher revenue but a net loss driven by investment fair value movements. Total revenue for the quarter ended June 30, 2026 was $119.6 million, with royalty revenue, net of capitalized fee amortization, of $56.3 million, net product sales of $51.8 million, and license and other revenue of $11.5 million. Income from operations was $50.9 million, but large negative changes in the fair values of equity method investments of $(131.8) million and equity and long-term investments of $(29.2) million led to a net loss of $(83.4) million, compared with net income of $63.7 million a year earlier.

For the first six months of 2026, total revenue was $217.6 million and net income was $103.2 million, indicating strong year-to-date profitability despite the second-quarter loss. Cash and cash equivalents were $570.4 million as of June 30, 2026, supported by $87.3 million of net cash provided by operating activities in the first half. The Innoviva Specialty Therapeutics platform generated U.S. net product sales of $36.6 million in the quarter, representing 26% year-over-year growth, and management stated it remains on track to achieve at least $150 million in IST U.S. net product sales in 2026. The company also highlighted a commercialization and licensing agreement with Dr. Reddy’s Laboratories for XACDURO in emerging markets and the launch of Nortiva Bio, a wholly owned strategic healthcare asset focused on extended-release oral drug delivery.

Vanguard Capital Management LLC, together with certain affiliates, reports beneficial ownership of 3,704,185 shares of Innoviva Inc common stock on a Schedule 13G. This position represents 5.01% of Innoviva’s outstanding common stock.

Vanguard reports sole voting power over 546,132 shares and sole dispositive power over all 3,704,185 shares, with no shared voting or dispositive power. Dividends and sale proceeds are generally for Vanguard-managed funds and accounts, and no other single person has an interest exceeding 5% of the class.

Innoviva, Inc. Chief Financial Officer Stephen Basso reported routine equity compensation activity. On May 15, 2026, he acquired 1,123 shares of common stock through the company’s Employee Stock Purchase Plan. On May 20, 2026, 559 shares were withheld to cover income taxes on vesting of earlier equity awards, leaving him with 88,571 shares held directly. The withholding is not an open-market sale and reflects tax obligations tied to prior grants.

Innoviva, Inc. Chief Executive Officer Pavel Raifeld reported routine equity compensation activity. On May 15, he acquired 1,123 shares of common stock at no cost through the Innoviva Employee Stock Purchase Plan. On May 20, 1,130 shares were withheld by Innoviva to cover income taxes on quarterly vesting of prior equity grants, leaving him holding 285,929 shares directly. These transactions reflect compensation and tax withholding, not open-market buying or selling.

Innoviva, Inc. reported a routine insider transaction by Chief Accounting Officer Marianne Zhen. On May 20, 2026, 1,127 shares of common stock were withheld by the company at $22.24 per share to cover income tax obligations tied to the quarterly vesting of prior equity grants.

These shares were not sold on the open market but used to satisfy tax withholding. After this tax-withholding disposition, Zhen directly holds 57,516 shares of Innoviva common stock.

Innoviva, Inc. director Linden Josephine reported equity compensation awards tied to their appointment to the Board on May 18, 2026. They received 9,461 shares of common stock and a separate 5,733-share restricted stock unit grant, all at no cash cost. In addition, they were granted non-statutory stock options for 9,166 shares of common stock at an exercise price of $21.80 per share, expiring in 2036. The RSUs vest over two years, while the options and additional RSUs vest at the earlier of the next annual stockholder meeting or one year after the grant date, subject to continued service and certain acceleration events.